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Introduction
First-in-human clinical trials represent a
critical juncture in the translation of
laboratory discoveries. However, because
they involve the greatest degree of uncer-
tainty at any point in the drug develop-
ment process, their initiation is beset by a
series of nettlesome ethical questions [1]:
has clinical promise been sufficiently
demonstrated in animals? Should trial
access be restricted to patients with
refractory disease? Should trials be viewed
as therapeutic? Have researchers ade-
quately minimized risks?
The resolution of such ethical questions
inevitably turns on claims about future
events like harms, therapeutic response,
and clinical translation. Recurrent failures
in clinical translation, like Eli Lilly’s
Alzheimer candidate semagacestat, high-
light the severe limitations of current
methods of prediction. In this case,
patients in the active arm of the placebo-
controlled trial had earlier onset of de-
mentia and elevated rates of skin cancer
[2].
Various authoritative accounts of hu-
man research ethics state that decision-
making about risk and benefit should be
careful, systematic, and non-arbitrary [3–
5]. Yet, these sources provide little guid-
ance about what kinds of evidence stake-
holders should use to ensure their esti-
mates of such events ground responsible
ethical decisions. In this article, we suggest
that investigators, oversight bodies, and
sponsors often base their predictions on a
flawed and inappropriately narrow pre-
clinical evidence base.
Prediction and Ethical Decision-
Making
According to the core tenets of human
research ethics, investigators, sponsors,
and institutional review boards (IRBs) are
obligated to ensure that risks to volunteers
are minimized and balanced favorably
with anticipated benefits to society and, if
applicable, to the volunteers themselves
[4,6]. Accurate prediction plays a critical
role in this process. When research teams
underestimate the probability of favorable
clinical or translational outcomes, they
undermine health care systems by imped-
ing clinical translation. When investigators
overestimate the probability of favorable
outcomes, they potentially expose individ-
uals to unjustified burdens, which may be
considerable for phase 1 studies involving
unproven drugs. In both cases, misestima-
tion threatens the integrity of the scientific
enterprise, because it frustrates prudent
allocation of research resources [7].
Naturally, there are limits to the reli-
ability with which forecasts based on
experimental evidence predict clinical
outcomes. However, in late stages of
clinical development, forecasts underwrit-
ing ethical and scientific decision-making
have proven fairly reliable. Several analy-
ses of cancer randomized controlled trials
indicate that new interventions are just as
likely to prove more effective than com-
parator ones as they were to prove inferior
[8–10]. Similar findings have been report-
ed for other indications [11]. In the
aggregate at least, researchers and review
committees neither overestimate nor un-
derestimate the medical benefits of allo-
cating some patients to new interventions
and others to standard drugs.
Whether decision-makers utilize evi-
dence as effectively when predicting out-
comes in early phase research has not
been systematically investigated. Never-
theless, there are grounds for concern such
that a systematic investigation is overdue.
Highly promising preclinical findings in
cancer, stroke, HIV vaccines, and neuro-
degenerative diseases frequently fail clini-
cal translation. In cancer, only 5% of
products entering trials are eventually
licensed [12,13]. In one study, approxi-
mately 5% of high impact basic science
reports were clinically translated within 10
years [14]. We suggest that these disap-
pointments partly reflect two problems in




First, decision-makers may not be
adequately responsive to problems in
preclinical research practice [15]. System-
atic reviews repeatedly demonstrate that
many animal studies do not enable reliable
causal inference and clinical generalization
because they do not address important
threats to internal, construct, and external
validity. With respect to the first, one
recent analysis of animal studies showed
that only 12% used random allocation and
14% used blinded outcome assessment
[16]. Construct validity concerns the
relationship between clinical implementa-
tion of an intervention and implementa-
tions evaluated in preclinical studies. A
recent review found that clinical studies of
cardiac arrest interventions applied treat-
ment significantly sooner after cardiac
events than in preclinical studies [17]. In
the case of Astra Zeneca’s failed stroke
drug NXY-059, use of normotensive
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have led to spurious predictions of clinical
activity [18]. Preclinical studies do not
always test the extent to which cause and
effect relationships hold up under varied
conditions (external validity). In a system-
atic review of neuroprotective agents in
phase 2 and 3 trials, only two of ten agents
were tested in both rodents and higher
order species [19]. Finally, deficiencies in
reporting and aggregation of preclinical
evidence deprive decision-makers of cru-
cial evidence. In one recent analysis,
publication bias in preclinical stroke stud-
ies led to a 30% overestimation of
treatment effect size [20]. Clearly, preclin-
ical researchers should endeavor to follow
reporting guidelines [21] such as the
recently proposed Animals In Research:
Reporting In Vivo Experiments Guidelines
(ARRIVE; http://www.nc3rs.org.uk/
page.asp?id=1357) [22], and clinical pre-
dictions following from animal studies
should take into account deficiencies in
design and reporting.
In the case of semegacestat, it has been
over 5 years since the drug was first tested
in human beings, and preclinical studies
have yet to be published. However, narra-
tive reviews by Eli Lilly scientists indicate
trials were launched on the basis of
molecular, rather than behavioral, end-
points [23]. Although the absence of
publication makes difficult any assessment
of animal study quality, the use of molec-
ular endpoints raises questions about the
construct validity of clinical generalizations
drawn from preclinical experiments.
Evidential Conservatism
A second concern about forecasting
outcomes in translational trials relates to
a tendency to base clinical inferences on a
relatively narrow class of evidence: those
preclinical studies that involve the partic-
ular agent. We call this ‘‘evidential con-
servatism.’’ Such evidential conservatism is
reflected in various policies. For example,
the American Society of Clinical Oncolo-
gy states that ‘‘the decision to move an
agent into phase I evaluation is based…
central[ly on]… the observation of suffi-
cient preclinical antitumor activity, such
that a therapeutic effect in human cancer
is anticipated’’ [24,25]. International
Council on Harmonization policy requires
investigators to furnish ethics review
committees with only a narrow type of
preclinical evidence [26]. Similarly, some
commentators argue that risk-benefit de-
cisions in early phase trials should be
driven by mechanistic evidence about an
agent [27].
Evidential conservatism, however, fails
to address the higher-order question of the
reliability of forecasts made from such a
narrow evidence base. This higher-order
question is of special relevance for early
phase research because agents that do not
enjoy the support of promising preclinical
results will not be plausible candidates for
translation. Yet when agents are supported
by equally promising preclinical results
they may be differentiated by the maturity
of the knowledge surrounding a nexus of
variables concerning the relationship be-
tween test and target populations.
For instance, although neuroprotective
stroke treatments have moved to transla-
tion on the basis of very encouraging
preclinical studies, they have consistently
failed randomized trials. Estimates of the
risks and benefits of any particular neuro-
protective compound that are based solely
on preclinical evaluation of that com-
pound will be less reliable than those that
incorporate information about the relative
success of neuroprotective compounds as a
class. In part, this is because the success or
failure of other interventions in this
reference class provides evidence about
the degree to which clinical development
is guided by a reliable working knowledge
of relevant disease processes.
Our claim that decision-makers need to
use a broader base of evidence for
evaluating early phase research is consis-
tent with a recent call for incorporating
whole research program outcomes into
systematic reviews of particular agents
[28].
Assessing Relevant Evidence
How might researchers depart from
evidential conservatisim in a way that is
open to scrutiny and amenable to assess-
ment, revision, and improvement? Deci-
sion-makers who make forecasts about
agent activity in early phase research must
identify reference classes that are relevant
to the decision at hand. Delimiting the
reference class of relevant evidence poses a
challenge in that interventions possess
limitless characteristics. A drug might be
classed within neuroprotective com-
pounds, stroke drugs, and drugs beginning
with the letter ‘‘n.’’ Decision-makers thus
confront the timeless problem of selecting
those characteristics most salient for pre-
diction.
There are no simple formulas here. In
some cases, choice of reference classes will
be straightforward (e.g., a new, small
molecule HMG-CoA reductase inhibitor);
in other cases, consensus may be elusive.
Nevertheless, we suggest that the very act
of attending to reference class identity
would be a departure from evidential
conservatism. As a starting place, deci-
sion-makers should identify reference
classes that index the maturity of knowl-
edge regarding central causal premises
embedded within a protocol. In an era in
which basic science heavily informs prod-
uct development, drug developers them-
selves often class their agents according to
explicit ambitions about causal pathways.
Asserting that a drug targets a particular
pathophysiologic process should prompt
us to look at how other drugs that target
the same process performed in clinical
translation. We can then base our esti-
mates of the maturity of knowledge about
these causal premises on the success or
failure of past attempts at redeeming these
ambitions. Decision-makers should there-
fore adjust their confidence in clinical
generalizations on the basis of outcomes
with previous interventions that addressed
the same pathological processes.
Semagacestat was screened and de-
signed to target amyloid-b production,
Summary Points
N Ethical judgments about risk, benefit, and patient eligibility in clinical trials
hinge on predictions about harm, therapeutic response, and clinical promise.
N Predictions for novel interventions in preclinical stages of development suffer
from two problems: insufficient attention to threats to validity in preclinical
research and a reliance on an overly narrow base of evidence that includes only
animal and clinical studies of the intervention in question (‘‘evidential
conservatism’’).
N To improve ethical and scientific decision-making in early phase studies,
decision-makers should explicitly attend to reporting quality and methodolog-
ical features in preclinical experiments that address threats to internal,
construct, and external validity.
N Decision-makers should also use evidence that sheds light on the reliability of
causal claims embedded within a proposed trial. This evidence can be gathered
from outcomes of previous trials involving agents targeting related biological
pathways (‘‘reference classes’’).
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dementia onset. Eight other anti-amyloid
drugs have either failed randomized
trials or been abandoned due to toxicity
(Table 1) [29,30]. Although a variant of
this approach may eventually succeed,
promising preclinical evidence supporting
semagecestat should have been tempered
by the accumulation of data about out-
comes in the same reference class.
Practical Implications
To illustrate how our suggestions inter-
face with ethical decision-making, consider
recent proposals to reinitiate trials of fetal-
derived tissues for Parkinson’s disease [31].
Previous trials involved treatment-refrac-
tory patients, but investigators are now
proposing trials involving patients with
recent onset. The rationale is that fetal-
derived tissues can only protect dopami-
nergic neurons to the extent that the latter
remain intact. However, the risk-benefit
balance is contentious, because the trial
will expose patients who can manage
symptoms with standard treatments to
the risks of neurosurgery, immunosuppres-
sion, and cell transplantation.
According to evidential conservatism,
investigators and ethics bodies should
evaluate the risk-benefit balance by con-
sulting preclinical studies and the biolog-
ical rationale for patient-subject selection.
One commentator notes that, on the basis
of preclinical studies showing the inter-
vention is designed to address early disease
processes, performing studies in patients
with advanced disease would be unethical
[27]. We think this way of using evidence
in ethical evaluation is misguided.
Our proposal directs decision-makers to
make risk-benefit decisions in light of two
additional factors. First, to what degree do
the preclinical studies incorporate design
elements that support reliable inferences
about clinical activity? This directs stake-
holders to attend to those methodological
features of the preclinical studies that
support credible claims of internal, con-
struct, and external validities in preclinical
studies. As these preclinical studies are
presently underway, researchers have an
opportunity to overcome past limitations
in addressing validity threats in Parkin-
son’s disease models [32].
Second, our proposal directs stakehold-
ers to consider evidence that sheds light on
the maturity of the knowledge relating to
key causal claims presupposed by thera-
peutic predictions. As investigators propose
to intervene in degenerative processes, a
claim of therapeutic action would need to
be evaluated in light of outcomes in
previous Parkinson’s trials involving surgi-
cally delivered neuroprotective agents and/
or transplanted tissues. No such strategies
have produced positive randomized trials
(Table 2). Accordingly, even with carefully
collected preclinical evidence, decision-
makers should approach new trials with
modest therapeutic expectations.
Thoughtful commentators have argued
that, before initiating cell-based dopamine
replacement, strategies should be ‘‘clini-
cally competitive’’ with standard of care
[33]. However, this may present an
unworkable standard [34]. Previous un-
successful attempts at translation betray
profound uncertainty concerning risks and
benefits for research volunteers. Given the
preliminary nature of such interventions,
the ethical justification for their adminis-
tration in early phase trials should not
hinge on the prospect of benefit for
volunteers. It should rest instead on a
compelling claim of knowledge value and
on the reduction of avoidable risks. The
latter entails pursuing trials in patients less
likely to suffer opportunity costs from
study participation, and maintaining a
background of medical management that
does not fall below standard of care.
Rather than being told that the approach
is comparable to standard of care, the
consent process should emphasize that
clinical benefit is unlikely.
Conclusion
Systematic study of preclinical research
has centered on stroke and practices
focused on internal validity. Our proposal
makes clear the need to broaden the scope
of this research agenda to cover a wider
range of preclinical research, and to
expand its focus to include issues of
construct and external validity. A key
component of this process will involve
creating databases for aggregating transla-
tional outcomes according to relevant
reference classes.
Some may worry that such an analysis
might produce less optimistic predictions,
and hence stymie product development.
However, we do not see how medicine is
advanced by forging ahead on the basis of
predictions of dubious reliability. More-
over, there are many productive ways in
which stakeholders may respond to less
optimistic projections. For instance, review
of relevant information may prompt
researchers to test certain hypotheses
before moving ahead with human trials.
Investigators might adjust the design of
translational studies to align the risk profile
with ethical judgments. Or, investigators
might decide that moving forward with a
protocol represents the best way to
advance a particular scientific initiative,
but that risks can only be justified by
appealing to the value of the knowledge
sought, rather than the product’s thera-
peutic activity.
Stakeholders might already adjust their
predictions in light of intuitions about
validity or experiences with success or
failure for similar agents. If so, they do so
on the basis of private beliefs, and often
without the data needed to make these
adjustments systematically. Our approach
Table 1. Outcomes in randomized trials of anti-amyloid drug candidates for Alzheimer’s disease.
Drug Phase Outcome Source
AN1792 2a Unacceptable toxicity [35]
Atorvastatin 3 No significance vs. placebo for two co-1u endpoints [36]
AZD-103 2 No significance vs. placebo for two co-1u endpoints; toxicity [37]
Bapineuzumab 2 No significance vs. placebo for 1u endpoint [38]
Phenserine 3 No significance vs. placebo in efficacy analysis [39]
Rosiglitiazone 3 No significance vs. placebo for two co-1u endpoints [40]
Tarenflurbil 3 No significance vs. placebo for two co-1u endpoints [41]
Tramiprostate 3 No significance vs. placebo for 1u endpoints [42]
doi:10.1371/journal.pmed.1001010.t001
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for making and adjudicating risk-benefit
predictions. We suggest that this would
better cohere with a sage prescription
offered by the National Commission:
‘‘there should first be a determination of
the validity of the presuppositions of the
research…. The method of ascertaining
risks should be explicit… It should also be
determined whether an investigator’s esti-
mates of the probability of harm or
benefits are reasonable, as judged by
known facts or other available studies ’’
[3].
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